Immune checkpoint inhibitors, durvalumab plus tremelimumab, for non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD, from Lausanne University Hospital, Lausanne, Switzerland, discusses a phase 1b trial that was designed to evaluate the safety and antitumour activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, combined with tremelimumab, an anti-CTLA-4 antibody, in patients with stage III/IV non-small cell lung cancer (NSCLC).